Home NDC 0597-0295 Synjardy
Product NDC 0597-0295
11-digit product format 005970295
Labeler code 0597
Product ID 0597-0295_09b6e275-e784-41d8-a75d-74a22f3e2eca
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name empagliflozin, metformin hydrochloride
Dosage form TABLET, EXTENDED RELEASE
Route ORAL
Labeler Boehringer Ingelheim Pharmaceuticals, Inc.
Application NDA208658
Marketing category NDA
Marketing start 2016-12-10
Substance EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Active strength 25; 1000 mg/1; mg/1
Pharmacologic classes Biguanide [EPC], Biguanides [CS], Sodium-Glucose Cotransporter 2 Inhibitor [EPC], Sodium-Glucose Transporter 2 Inhibitors [MoA]
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 1 .
Orange Book products# Current product rows page 1 of 1 · 4 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N208658-001 SYNJARDY XR EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE 5MG;1GM TABLET, EXTENDED RELEASE / ORAL RLD 2016-12-09 N208658-002 SYNJARDY XR EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE 10MG;1GM TABLET, EXTENDED RELEASE / ORAL RLD 2016-12-09 N208658-003 SYNJARDY XR EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE 12.5MG;1GM TABLET, EXTENDED RELEASE / ORAL RLD 2016-12-09 N208658-004 SYNJARDY XR EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE 25MG;1GM TABLET, EXTENDED RELEASE / ORAL RLD, RS 2016-12-09
Orange Book patents# Current patent rows page 1 of 2 · 124 matching rows.
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 8 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-08-01 22:54:32 2026-06 N208658-001 SYNJARDY XR 5MG;1GM TABLET, EXTENDED RELEASE / ORAL RLD 2016-12-09 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-002 SYNJARDY XR 10MG;1GM TABLET, EXTENDED RELEASE / ORAL RLD 2016-12-09 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-003 SYNJARDY XR 12.5MG;1GM TABLET, EXTENDED RELEASE / ORAL RLD 2016-12-09 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-004 SYNJARDY XR 25MG;1GM TABLET, EXTENDED RELEASE / ORAL RLD, RS 2016-12-09 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 4 · 124 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-08-01 22:54:32 2026-06 N208658-001 7713938 2027-04-15 Drug substance, Drug product 2017-01-04 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 7713938*PED 2027-10-15 Pediatric extension a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 7579449 2028-08-01 Drug substance 2017-01-04 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 7579449*PED 2029-02-01 Pediatric extension a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 12115179 2030-02-11 U-4023 2024-11-12 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 12115179*PED 2030-08-11 Pediatric extension a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 10596120 2032-03-07 U-2775 Drug product 2020-04-20 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 10596120 2032-03-07 U-2792 Drug product 2020-04-20 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 10596120*PED 2032-09-07 Pediatric extension a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 10258637 2034-04-03 U-2290 2019-04-30 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 11090323 2034-04-03 U-3193 2021-08-20 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 11666590 2034-04-03 U-4154 2025-03-28 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 11813275 2034-04-03 U-3759 2023-12-13 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 11833166 2034-04-03 U-3776 2024-01-03 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 11833166 2034-04-03 U-3777 2024-01-03 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 12263153 2034-04-03 U-4154 2025-04-29 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 12427162 2034-04-03 U-4287 2025-10-29 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 12433906 2034-04-03 U-4304 2025-10-29 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 12433906 2034-04-03 U-4293 2025-10-29 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 12433906 2034-04-03 U-4294 2025-10-29 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 12433906 2034-04-03 U-4295 2025-10-29 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 12433906 2034-04-03 U-4296 2025-10-29 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 9949997 2034-05-17 U-3532 2023-03-01 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 9949997 2034-05-17 U-3533 2023-03-01 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 9949998 2034-06-11 U-2290 2018-05-16 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 10258637*PED 2034-10-03 Pediatric extension a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 11090323*PED 2034-10-03 Pediatric extension a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 11813275*PED 2034-10-03 Pediatric extension a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 11833166*PED 2034-10-03 Pediatric extension a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 12433906*PED 2034-10-03 Pediatric extension a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 9949997*PED 2034-11-17 Pediatric extension a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-001 9949998*PED 2034-12-11 Pediatric extension a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-002 7713938 2027-04-15 Drug substance, Drug product 2017-01-04 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-002 7713938*PED 2027-10-15 Pediatric extension a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-002 7579449 2028-08-01 Drug substance 2017-01-04 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-002 7579449*PED 2029-02-01 Pediatric extension a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-002 12115179 2030-02-11 U-4023 2024-11-12 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-002 12115179*PED 2030-08-11 Pediatric extension a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-002 10596120 2032-03-07 U-2775 Drug product 2020-04-20 a50c72e98297…2026-08-01 22:54:32 2026-06 N208658-002 10596120 2032-03-07 U-2792 Drug product 2020-04-20 a50c72e98297…
Observed Orange Book exclusivity history# openFDA label cross-check# Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join Synjardy XR EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE Boehringer Ingelheim Pharmaceuticals, Inc. 8006ba29-ee3a-f852-a9bb-c8ec9b41cf66 2026-01-20 Boxed warning, Warnings, Adverse reactions Exact identifier application applno (NDA): 208658 application number: NDA208658 ndc (product): 0597-0295
Additional Listing Data#
Finished product Yes
Brand name base Synjardy
Brand name suffix XR
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength EMPAGLIFLOZIN 25 mg/1 METFORMIN HYDROCHLORIDE 1000 mg/1
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 2 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination HDC1R2M35U Internal UNII lookup 786Z46389E Internal UNII lookup
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 8 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 1862685 Internal RxNorm lookup 1862688 Internal RxNorm lookup 1862691 Internal RxNorm lookup 1862692 Internal RxNorm lookup 1862695 Internal RxNorm lookup 1862697 Internal RxNorm lookup 1862700 Internal RxNorm lookup 1862701 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 0597-0295-61 SynjardyXR 7 in 1 BOTTLE TABLET, EXTENDED RELEASE 7 17 0597-0295-61 SynjardyXR 1 in 1 CARTON TABLET, EXTENDED RELEASE 1 17 0597-0295-78 SynjardyXR 90 in 1 BOTTLE TABLET, EXTENDED RELEASE 90 17 0597-0295-88 SynjardyXR 30 in 1 BOTTLE TABLET, EXTENDED RELEASE 30 17
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 0597-0295 SYNJARDY XR (EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE) TABLET, EXTENDED RELEASE [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.] 14 Current NDC, Legacy NDC, 4 package rows 20250323_8006ba29-ee3a-f852-a9bb-c8ec9b41cf66.zip
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Marketing end Sample Exclude flag Status 0597-0295-61 00597029561 1 BOTTLE in 1 CARTON (0597-0295-61) / 7 TABLET, EXTENDED RELEASE in 1 BOTTLE 1 bottle 2016-12-10 0000-00-00 Yes No Current 0597-0295-78 00597029578 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0295-78) 2016-12-10 0000-00-00 No No Current 0597-0295-88 00597029588 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0597-0295-88) 2016-12-10 0000-00-00 No No Current